Atlanta Neuroscience Institute

Atlanta, Georgia 30327

1 studies enrolling now · 11 studies all time

What they study most

Alzheimer Disease, Multiple Sclerosis, Multiple Sclerosis (MS), Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis, Relapsing, Multiple Sclerosis, Relapsing-Remitting, Parkinson Disease, Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS)

Studies at this site

• Effects of Ublituximab on Motor Functions in Multiple Sclerosis — Recruiting now
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab — Running, not enrolling
• To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Running, not enrolling
• An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab — Completed
• Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab — Completed
• Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) — Running, not enrolling
• The MS-LINK™ Outcomes Study — Completed
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed
• Next-Gen MS: Feed-forward PRO Data for MS Research — Stopped early
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed